Strides Arcolab is currently trading at Rs. 608.00, up by 5.05 points or 0.84% from its previous closing of Rs. 602.95 on the BSE.
The scrip opened at Rs. 604.10 and has touched a high and low of Rs. 610.00 and Rs. 602.45 respectively. So far 8068 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 628.50 on 02-Apr-2012 and a 52 week low of Rs. 276.25 on 22-Aug-2011.
Last one week high and low of the scrip stood at Rs. 628.50 and Rs. 573.00 respectively. The current market cap of the company is Rs. 3559.54 crore.
The promoters holding in the company stood at 28.42% while Institutions and Non-Institutions held 54.49% and 17.09% respectively.
Strides Arcolab has received approval from Health Canada for Tobramycin Injection USP 40 mg / mL, Liquid dosage form. Tobramycin is in a group of antibiotics called aminoglycosides used to treat bacterial infections of the skin, heart, stomach, brain and spinal cord, respiratory system, and urinary tract. It is also used in the treatment of cystic fibrosis. Tobramycin injection is sometimes used together with other antibiotics.
The approval was granted under the expedited review process being adopted by Health Canada to address the severe drug shortage situation in Canada. In March 2012, Canadian Health Ministry had indicated that Health Canada will approve suppliers within a month to ease the drug shortage in Canada.
The market value of the product is approximately $4.2 million. The product will be commercialized in Q2 of 2012 directly by Strides Canadian subsidiary.
Strides Arcolab is a global pharmaceuticals headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceuticals products with an emphasis on sterile injectables.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: